Kristoph Jahnke

Summary

Affiliation: Humboldt University
Country: Germany

Publications

  1. pmc Diagnosis and management of primary intraocular lymphoma: an update
    Kristoph Jahnke
    Department of Hematology, Oncology and Transfusion Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    Clin Ophthalmol 1:247-58. 2007
  2. ncbi request reprint Randomized phase II study of paclitaxel and carboplatin or vinorelbine in advanced non-small cell lung cancer
    Kristoph Jahnke
    Department of Hematology and Oncology, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    Anticancer Res 31:317-23. 2011
  3. doi request reprint Treatment options for central nervous system lymphomas in immunocompetent patients
    Kristoph Jahnke
    Department of Hematology and Oncology, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, D 12200 Berlin, Germany
    Expert Rev Neurother 9:1497-509. 2009
  4. doi request reprint Ifosfamide or trofosfamide in patients with intraocular lymphoma
    Kristoph Jahnke
    Department of Hematology and Oncology, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Germany
    J Neurooncol 93:213-7. 2009
  5. ncbi request reprint Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes
    Kristoph Jahnke
    Department of Hematology, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    J Clin Oncol 24:4754-7. 2006
  6. ncbi request reprint Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors
    Kristoph Jahnke
    Department of Hematology, Oncology and Transfusion Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, D 12200, Berlin, Germany
    J Neurooncol 80:159-65. 2006
  7. ncbi request reprint Intraocular lymphoma 2000-2005: results of a retrospective multicentre trial
    Kristoph Jahnke
    Department of Haematology, Oncology and Transfusion Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Graefes Arch Clin Exp Ophthalmol 244:663-9. 2006
  8. ncbi request reprint Pharmacokinetics and efficacy of ifosfamide or trofosfamide in patients with intraocular lymphoma
    K Jahnke
    Department of Haematology, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    Ann Oncol 16:1974-8. 2005
  9. ncbi request reprint Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system
    Kristoph Jahnke
    Department of Hematology, Oncology and Transfusion Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Hematol 85:45-50. 2006
  10. ncbi request reprint Treatment of primary intraocular lymphoma with oral trofosfamide: report of two cases and review of the literature
    Kristoph Jahnke
    Department of Hematology, Oncology and Transfusion Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Graefes Arch Clin Exp Ophthalmol 242:771-6. 2004

Detail Information

Publications34

  1. pmc Diagnosis and management of primary intraocular lymphoma: an update
    Kristoph Jahnke
    Department of Hematology, Oncology and Transfusion Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    Clin Ophthalmol 1:247-58. 2007
    ..Future directions in the management of PIOL should include studies about pathogenesis, prognostic factors, and treatment optimization. In the future, monoclonal antibodies and radioimmunotherapy could prove useful for PIOL treatment...
  2. ncbi request reprint Randomized phase II study of paclitaxel and carboplatin or vinorelbine in advanced non-small cell lung cancer
    Kristoph Jahnke
    Department of Hematology and Oncology, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    Anticancer Res 31:317-23. 2011
    ..A randomized phase II trial was conducted to determine if two non-platinum protocols are able to yield a similar efficacy and toxicity profile as compared to two platinum-based doublets in advanced non-small cell lung cancer (NSCLC)...
  3. doi request reprint Treatment options for central nervous system lymphomas in immunocompetent patients
    Kristoph Jahnke
    Department of Hematology and Oncology, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, D 12200 Berlin, Germany
    Expert Rev Neurother 9:1497-509. 2009
    ..Future directions in the management of PCNSL and CNS relapse of systemic lymphoma may include treatment stratification according to patient age and clinical and biological prognostic factors...
  4. doi request reprint Ifosfamide or trofosfamide in patients with intraocular lymphoma
    Kristoph Jahnke
    Department of Hematology and Oncology, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Germany
    J Neurooncol 93:213-7. 2009
    ..IFO or TRO were active and well tolerated in this study. Thus, they may represent suitable combination partners for other cytostatics used for PCNSL and IOL treatment...
  5. ncbi request reprint Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes
    Kristoph Jahnke
    Department of Hematology, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    J Clin Oncol 24:4754-7. 2006
    ....
  6. ncbi request reprint Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors
    Kristoph Jahnke
    Department of Hematology, Oncology and Transfusion Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, D 12200, Berlin, Germany
    J Neurooncol 80:159-65. 2006
    ..Survival of patients with relapsed PCNSL is poor despite high response rates to salvage therapy. Good KPS, isolated systemic relapse and treatment for relapse were significantly associated with longer survival...
  7. ncbi request reprint Intraocular lymphoma 2000-2005: results of a retrospective multicentre trial
    Kristoph Jahnke
    Department of Haematology, Oncology and Transfusion Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Graefes Arch Clin Exp Ophthalmol 244:663-9. 2006
    ..The prognosis of intraocular lymphoma (IOL) is poor, and the optimal treatment has yet to be defined. This study assesses the clinical characteristics and outcome of patients with IOL diagnosed and treated in the new millennium...
  8. ncbi request reprint Pharmacokinetics and efficacy of ifosfamide or trofosfamide in patients with intraocular lymphoma
    K Jahnke
    Department of Haematology, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    Ann Oncol 16:1974-8. 2005
    ..The prognosis of intraocular lymphoma (IOL) is poor, and the optimal treatment has not yet been defined. The study assesses ifosfamide (IFO) and trofosfamide (TRO) for treating IOL...
  9. ncbi request reprint Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system
    Kristoph Jahnke
    Department of Hematology, Oncology and Transfusion Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Hematol 85:45-50. 2006
    ..In conclusion, long-term survival can be achieved in patients with secondary CNS lymphoma. LDH at CNS manifestation and a CNS response to therapy were significantly associated with survival...
  10. ncbi request reprint Treatment of primary intraocular lymphoma with oral trofosfamide: report of two cases and review of the literature
    Kristoph Jahnke
    Department of Hematology, Oncology and Transfusion Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Graefes Arch Clin Exp Ophthalmol 242:771-6. 2004
    ..The prognosis of primary intraocular lymphoma (PIOL) is poor. Due to frequent ocular and/or CNS relapses, the optimal treatment for PIOL has not yet been defined. This is the first report of PIOL treatment with trofosfamide...
  11. ncbi request reprint High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma
    K Jahnke
    Department of Hematology, Oncology and Transfusion Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Oncol 16:445-9. 2005
    ..We evaluated HDMTX-related toxicity with special regard to age distribution in patients with primary central nervous system lymphoma (PCNSL) in a phase IV multicenter trial...
  12. ncbi request reprint Long distance polymerase chain reaction of ascites lymphoma cells aids diagnosis establishment of abdominal Burkitt's lymphoma and Burkitt-like lymphoma
    Kristoph Jahnke
    Department of Hematology, Oncolgy and Transfusion Medicine, Charite Universitatsmedizin Berlin, Germany
    Leuk Lymphoma 46:83-6. 2005
    ..Long distance PCR analysis of ascites lymphoma cells for the detection of the BL-typical c-myc rearrangement offers a convenient and rapid possibility of diagnosis verification in atypical or borderline cases of BL...
  13. ncbi request reprint Low-grade primary central nervous system lymphoma in immunocompetent patients
    Kristoph Jahnke
    Department of Haematology, Oncology and Transfusion Medicine, Charite Universitatsmedizin Berlin, D 12200 Berlin, Germany
    Br J Haematol 128:616-24. 2005
    ..Low-grade PCNSL may differ from classical high-grade PCNSL in its clinical features and radiological morphology. The clinical course may be variable and frequently more indolent than in classical PCNSL...
  14. doi request reprint High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial
    Eckhard Thiel
    Department of Hematology and Oncology, Charite Berlin, Berlin, Germany
    Lancet Oncol 11:1036-47. 2010
    ..We aimed to investigate whether first-line chemotherapy based on high-dose methotrexate was non-inferior to the same chemotherapy regimen followed by whole brain radiotherapy for overall survival...
  15. doi request reprint Systemic high-dose methotrexate plus ifosfamide is highly effective for central nervous system (CNS) involvement of lymphoma
    Lars Fischer
    Department of Hematology, Oncology and Transfusion Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    Ann Hematol 88:133-9. 2009
    ..The median overall survival was not reached. Systemic chemotherapy with HDMTX/IFO is a feasible and promising treatment modality for CNS relapse of a malignant lymphoma...
  16. ncbi request reprint International study on low-grade primary central nervous system lymphoma
    Kristoph Jahnke
    Department of Hematology, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    Ann Neurol 59:755-62. 2006
    ..The aim of this study was to characterize the clinical presentation, course, and outcome of low-grade primary central nervous system lymphoma...
  17. ncbi request reprint Radiologic morphology of low-grade primary central nervous system lymphoma in immunocompetent patients
    Kristoph Jahnke
    Department of Hematology, Oncology and Transfusion Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    AJNR Am J Neuroradiol 26:2446-54. 2005
    ..We evaluated the radiologic morphology and clinical characteristics of low-grade PCNSLs, hypothesizing that they may differ from high-grade PCNSLs...
  18. pmc First report on a prospective trial with yttrium-90-labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma
    Sofiane Maza
    Department of Hematology, Oncology, and Transfusion Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30 31, 12200 Berlin, Germany
    Neuro Oncol 11:423-9. 2009
    ..Because of limited response duration and considerable hematotoxicity, future investigations should focus on a multimodal approach with additional chemotherapy and preferably autologous stem cell support...
  19. pmc Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model
    Kristoph Jahnke
    Charite Universitatsmedizin Berlin, Campus Benjamin Franklin Medizinische Klinik m S Hämatologie und Onkologie, Berlin, Germany
    Neuro Oncol 11:142-50. 2009
    ..The promising survival data warrant future clinical trials using bevacizumab + carboplatin...
  20. ncbi request reprint Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma
    Agnieszka Korfel
    Department of Haematology, Oncology and Transfusion Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    Br J Haematol 128:177-83. 2005
    ..2 vs. 9.9 months, P = 0.02). Median survival was significantly longer at institutions accruing at least four patients than at those with fewer patients (31.5 vs. 9.5 months, P = 0.03)...
  21. ncbi request reprint Relapse of primary extranodal marginal-zone B-cell lymphoma of the dura mater
    Chalid Assaf
    Department of Dermatology, Charite University Medicine Berlin, Campus Benjamin Franklin, Berlin, Germany
    Lancet Oncol 6:187-9. 2005
  22. ncbi request reprint Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan
    L Fischer
    Department of Hematology, Oncology, and Transfusion Medicine, Klinikum Benjamin Franklin, Freie Universitat Berlin, Germany
    Neurology 62:1885-7. 2004
    ..Four complete remissions and two partial remissions were achieved. Progression-free survival was 20% at 6 months and 13% at 12 months...
  23. ncbi request reprint Unusual sites of Hodgkin's lymphoma: CASE 3. Cholemic nephrosis in Hodgkin's lymphoma with liver involvement
    Philipp Kiewe
    Charite University Medicine, Campus Benjamin Franklin, Berlin, Germany
    J Clin Oncol 22:4230-1. 2004
  24. ncbi request reprint Prospective trial on topotecan salvage therapy in primary CNS lymphoma
    L Fischer
    Department of Haematology, Oncology and Transfusion Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Germany
    Ann Oncol 17:1141-5. 2006
    ..Standard salvage therapy has not been established for recurrent primary central nervous system lymphoma (PCNSL). We report the final results of a prospective study on topotecan chemotherapy in relapsed or refractory PCNSL...
  25. ncbi request reprint Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma
    Nancy D Doolittle
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
    Leuk Lymphoma 48:1712-20. 2007
    ....
  26. ncbi request reprint Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report
    Nancy D Doolittle
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
    Blood 111:1085-93. 2008
    ..Our results suggest systemic methotrexate is the optimal treatment for isolated CNS relapse involving the brain parenchyma. Long-term survival is possible in some patients...
  27. ncbi request reprint Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system
    Kristoph Jahnke
    Department of Neurology, Oregon Health and Science University, Portland, Oregon 97239 3098, USA
    Cancer 112:581-8. 2008
    ..Intraarterial chemotherapy and osmotic blood-brain barrier disruption (IA/BBBD) increases drug delivery to the CNS...
  28. ncbi request reprint Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group
    Tamara N Shenkier
    British Columbia Cancer Agency, 600 W 10th Ave, Vancouver, BC, V5Z 4E6, Canada
    J Clin Oncol 23:2233-9. 2005
    ..To describe the demographic and tumor related characteristics and outcomes for patients with primary T-cell CNS lymphoma (TPCNSL)...
  29. ncbi request reprint Chemotherapy delivery issues in central nervous system malignancy: a reality check
    Leslie L Muldoon
    Department of Neurology, Oregon Health and Science University, Portland, and the Veterans Administration Medical Center, OR 97239 3098, USA
    J Clin Oncol 25:2295-305. 2007
    ..This review assesses the current state of knowledge regarding preclinical and clinical pharmacology for brain tumor chemotherapy and evaluates relevant brain tumor pharmacology studies before October 2006...
  30. ncbi request reprint Characterization and magnetic resonance imaging of a rat model of human B-cell central nervous system lymphoma
    Carole Soussain
    Department of Neurology, Oregon Health and Science University, Portland, Oregon 97239 3098, USA
    Clin Cancer Res 13:2504-11. 2007
    ..The incidence of primary central nervous system lymphoma (PCNSL) is increasing. Therapeutic approaches remain controversial. An animal model that mimics the clinical situation would be useful for evaluating PCNSL biology and treatment...
  31. ncbi request reprint Distinguishing primary central nervous system lymphoma from other central nervous system diseases: a neurosurgical perspective on diagnostic dilemmas and approaches
    Matthew A Hunt
    Department of Neurosurgery, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, L603 Portland, Oregon 97239 3098, USA
    Neurosurg Focus 21:E3. 2006
    ..Unfortunately, delayed diagnosis and treatment of PCNSL can negatively affect prognosis...
  32. ncbi request reprint Implications of the blood-brain barrier in primary central nervous system lymphoma
    Kristoph Jahnke
    Department of Neurology, Oregon Health and Science University, Portland, Oregon, USA
    Neurosurg Focus 21:E11. 2006
    ..Regarding the evaluation of more sensitive and specific diagnostic imaging tools, iron oxide-based contrast agents for magnetic resonance imaging have shown promise for better differentiation of PCNSL from other white matter diseases...
  33. ncbi request reprint The diagnostic value of cerebrospinal fluid pleocytosis and protein in the detection of lymphomatous meningitis in primary central nervous system lymphomas
    Lars Fischer
    Haematologica 91:429-30. 2006
    ..Pleocytosis correlated with positive cytology, whereas CSF protein did not (specificity cell count vs. protein 74% vs. 34% [p<0.001], sensitivity 86% vs. 62% [p=0.18])...
  34. ncbi request reprint Expression of the chemokine receptors CXCR4, CXCR5, and CCR7 in primary central nervous system lymphoma
    Kristoph Jahnke
    Blood 106:384-5. 2005